Telix Pharmaceuticals (TLX) Enterprise Value (2023 - 2025)

Telix Pharmaceuticals (TLX) has disclosed Enterprise Value for 3 consecutive years, with -$141.9 million as the latest value for Q4 2025.

  • Quarterly Enterprise Value rose 69.46% to -$141.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$141.9 million through Dec 2025, up 69.46% year-over-year, with the annual reading at -$141.9 million for FY2025, 69.46% up from the prior year.
  • Enterprise Value for Q4 2025 was -$141.9 million at Telix Pharmaceuticals, up from -$464.5 million in the prior quarter.
  • The five-year high for Enterprise Value was -$80.2 million in Q4 2023, with the low at -$464.5 million in Q4 2024.
  • Average Enterprise Value over 3 years is -$228.9 million, with a median of -$141.9 million recorded in 2025.
  • The sharpest move saw Enterprise Value crashed 479.03% in 2024, then soared 69.46% in 2025.
  • Over 3 years, Enterprise Value stood at -$80.2 million in 2023, then plummeted by 479.03% to -$464.5 million in 2024, then soared by 69.46% to -$141.9 million in 2025.
  • According to Business Quant data, Enterprise Value over the past three periods came in at -$141.9 million, -$464.5 million, and -$80.2 million for Q4 2025, Q4 2024, and Q4 2023 respectively.